Observational Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. Sep 9, 2021; 10(5): 244-259
Published online Sep 9, 2021. doi: 10.5492/wjccm.v10.i5.244
Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital
Jose I Iglesias, Andrew V Vassallo, Jesse B Sullivan, Yasmine Elbaga, Vishal V Patel, Nikunjkumar Patel, Lydia Ayad, Payam Benson, Marina Pittiglio, Emad Gobran, Alexander Clark, Wajahat Khan, Kaliope Damalas, Rajesh Mohan, Satyendra P Singh
Jose I Iglesias, Wajahat Khan, Department of Critical Care, Community Medical Center, Toms River, NJ 08757, United States
Jose I Iglesias, Department of Nephrology, Community Medical Center, Toms River, NJ 08757, United States
Jose I Iglesias, Department of Nephrology, Jersey Shore University Medical Center, Hackensack Meridian School of Medicine at Seton Hall, Neptune, NJ 07753, United States
Andrew V Vassallo, Vishal V Patel, Marina Pittiglio, Kaliope Damalas, Department of Pharmacy, Community Medical Center, Toms River, NJ 08757, United States
Jesse B Sullivan, Fairleigh Dickinson University School of Pharmacy & Health Sciences, Fairleigh Dickinson University, Florham Park, NJ 07932, United States
Yasmine Elbaga, Alexander Clark, Department of Pharmancy, Monmouth Medical Center Southern Campus, Lakewood, NJ 08701, United States
Nikunjkumar Patel, Lydia Ayad, Payam Benson, Emad Gobran, Department of Medicine, Community Medical Center, Toms River, NJ 08757, United States
Rajesh Mohan, Department of Cardiology, Monmouth Medical Center Southern Campus, Lakewood, NJ 08701, United States
Satyendra P Singh, Department of Medicine, Monmouth Medical Center Southern Campus, Lakewood, NJ 08701, United States
Author contributions: Iglesias JI and Vassallo AV contributed to conceptualization, methodology, and formal analysis; Iglesias JI, Vassallo AV, Sullivan JB, Elbaga Y and Patel VV wrote the original draft; Data collection along with manuscript review and editing was performed by Iglesias JI, Vassallo AV, Elbaga Y, Patel N, Gobran E, Ayad L, Pittiglio M, Khan W, Benson P, Damalas K, Clark A, Singh SP, and Mohan R.
Institutional review board statement: The study was approved by the Community Medical Center Institutional Review Board (IRB # 20-005).
Informed consent statement: Informed consent was waived by the Community Medical Center Institutional Review Board as the study was deemed minimal risk to participants due to its retrospective nature and de-identified results.
Conflict-of-interest statement: None of the listed authors have any conflicts of interest to disclose.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE statement, and the manuscript was prepared and revised according to the STROBE statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jose I Iglesias, DO, Associate Professor, Department of Critical Care, Community Medical Center, 99 W Rt 37, Toms River, NJ 08757, United States. jiglesias23@gmail.com
Received: April 21, 2021
Peer-review started: April 21, 2021
First decision: June 17, 2021
Revised: June 23, 2021
Accepted: August 4, 2021
Article in press: August 4, 2021
Published online: September 9, 2021
Processing time: 140 Days and 17.9 Hours
Core Tip

Core Tip: Anti-inflammatory therapy with glucocorticoids (including methylpredsnisolone) and combination treatment with tocilizumab and glucocorticoids improve survival in critically ill patients with coronavirus disease 2019. Dual inhibition of the NFK-β therapy with glucocorticoid and inhibition of the interleukin-6 pathway with tocilizumab may offer greater survival benefits.